ADMA Biologics (ADMA): Firm updates 2025 revenue guidance
I'm PortAI, I can summarize articles.
ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the Stocks That Could Mint Millionaires in 2026. ADMA Biologics, Inc. (NASDAQ:ADMA) markets BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency, and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and […]
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments